Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

71.97 -1.08 (-1.49%)
Streaming Delayed Price Updated: 9:39 AM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Agenda for Virtual R&D Day
From Apogee Therapeutics
Via GlobeNewswire
News headline image
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024 ↗
APGE stock results show that Apogee Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
News headline image
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 ↗
APGE stock results show that Apogee Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter ↗
Discover how Nvidia, Apogee Therapeutics and JD.com stand out as earnings outperformers in their respective sectors. 
Via InvestorPlace
News headline image
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.